RadNet Inc
NASDAQ:RDNT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (2.2), the stock would be worth $59.3 (2% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.1 | $57.89 |
0%
|
| 3-Year Average | 2.2 | $59.3 |
+2%
|
| 5-Year Average | 1.5 | $40.28 |
-30%
|
| Industry Average | 1.7 | $48.08 |
-17%
|
| Country Average | 2.4 | $67.12 |
+16%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$4.1B
|
/ |
Jan 2026
$2B
|
= |
|
|
$4.1B
|
/ |
Dec 2026
$2.5B
|
= |
|
|
$4.1B
|
/ |
Dec 2027
$2.8B
|
= |
|
|
$4.1B
|
/ |
Dec 2028
$3.1B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
RadNet Inc
NASDAQ:RDNT
|
4.3B USD | 2.1 | -229.8 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
102.9B USD | 0.3 | 58.2 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
70.3B EUR | 0.3 | 13.6 | |
| US |
|
Cigna Corp
NYSE:CI
|
75.1B USD | 0.3 | 12.6 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.6B EUR | 1.1 | 23.1 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23B EUR | 1 | 18.2 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.7B USD | 1.9 | 21.2 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.3B USD | 1.5 | 24.3 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 0.6 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
10.9B USD | 11.1 | -26.1 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.3B USD | 0.8 | 13.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
RadNet Inc
Glance View
RadNet Inc. stands as a formidable entity in the realm of diagnostic imaging services, charting its course as a crucial component within the broader healthcare sector. Founded in 1980, the company has evolved into a vital provider of outpatient imaging services across the United States, leveraging both organic growth and strategic acquisitions. RadNet operates a network of imaging centers, equipped with cutting-edge technology and staffed by experienced radiologists and technicians. These centers offer a range of diagnostic imaging procedures, including MRI, CT, mammography, X-ray, and ultrasound. By positioning itself at the intersection of healthcare efficiency and innovation, RadNet marries technology with patient care, optimizing the process of disease detection and diagnosis. Revenue streams for RadNet primarily flow from patient payments and insurance reimbursements for services rendered. With the increasing reliance on advanced imaging techniques in modern medicine, RadNet capitalizes on the demand for accurate, timely diagnostic data from healthcare providers aiming to enhance patient care protocols. Another key revenue avenue stems from partnerships with hospitals and healthcare systems, wherein RadNet provides the technical platform and expertise, thus enabling these institutions to focus on core patient care activities. This business model not only underscores the importance of diagnostic services in preventive and restorative healthcare but also sharpens RadNet’s competitive edge through scale, efficiency, and an extensive network of service locations.
